His study deals with a combination of Internal medicine and Psychiatry. He undertakes multidisciplinary investigations into Psychiatry and Internal medicine in his work. His work blends Oncology and Gastroenterology studies together. In his papers, Martin J. van den Bent integrates diverse fields, such as Gastroenterology and Oncology. In his papers, he integrates diverse fields, such as Cancer research and Cancer. Martin J. van den Bent conducted interdisciplinary study in his works that combined Cancer and Radiation therapy. He integrates Radiation therapy with Astrocytoma in his study. His Astrocytoma study frequently draws parallels with other fields, such as Oligodendroglial Tumor. His Oligodendroglial Tumor study frequently draws connections between adjacent fields such as Oligodendroglioma.
His Internal medicine study often links to related topics such as Randomized controlled trial. With his scientific publications, his incorporates both Oncology and Cancer. His Cancer research study frequently draws connections between related disciplines such as Glioblastoma. Glioma is closely attributed to Genetics in his work. Genetics is frequently linked to Glioma in his study. Martin J. van den Bent performs multidisciplinary studies into Chemotherapy and Surgery in his work. He performs integrative Surgery and Chemotherapy research in his work. His work blends Temozolomide and Radiation therapy studies together. He performs multidisciplinary study on Radiation therapy and Temozolomide in his works.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller.
The New England Journal of Medicine (2005)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent.
Lancet Oncology (2009)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Dieta Brandsma;Lukas Stalpers;Walter Taal;Peter Sminia.
Lancet Oncology (2008)
Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Francesco Pignatti;Martin van den Bent;Desmond Curran;Channa Debruyne.
Journal of Clinical Oncology (2002)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros.
Journal of Clinical Oncology (2013)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge.
Lancet Oncology (2014)
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson.
Journal of Clinical Oncology (2006)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal;Hendrika M Oosterkamp;Annemiek M E Walenkamp;Hendrikus J Dubbink.
Lancet Oncology (2014)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp.
Lancet Oncology (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: